A retrospective study of PD-1 and PD-1L antobodies (Ipilimumab,Nivolumab,Pembrolizumab and Atezolizumab) in patients with uveal melanoma

Trial Profile

A retrospective study of PD-1 and PD-1L antobodies (Ipilimumab,Nivolumab,Pembrolizumab and Atezolizumab) in patients with uveal melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2016 Results published in the Cancer.
    • 14 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top